Characteristics of Patients with Clostridium Difficile Infection in Taiwan

Overview

Journal Epidemiol Infect

Publisher Cambridge University Press

Specialties Infectious Diseases
Public Health

Date 2012 Dec 11

PMID 23218131

Citations 3

Authors

Y-C Lin

Y-T Huang

T-F Lee

N-Y Lee

C-H Liao

S-Y Lin

W-C Ko

P-R Hsueh

Affiliations

Soon will be listed here.

Abstract

The medical records of 84 patients with stool cultures positive for Clostridium difficile during the period August 2007 to June 2009 were retrospectively reviewed. A case of confirmed (toxigenic)C. difficile infection (CDI) was defined by the presence of symptoms (fever, diarrhoea, abdominal discomfort or distension, ileus) and the presence of toxigenic C. difficile. Patients with compatible clinical symptoms and stool cultures positive for non-toxigenic C. difficile isolates were defined as probable (non-toxigenic) CDI cases. Of these 84 patients, 50 (59.5%) were diagnosed as confirmed CDI and 34 (40.5%) as probable CDI. Thirteen (15.5%) of the 84 patients died during their hospital stay. Usage of proton pump inhibitors was a significant independent risk factor for CDI (OR 3.21, P=0.014). Of the 50 isolates associated with confirmed CDI, seven (8.3%) carried binary toxin genes (cdtAB), and six (7.1%) had a deletion in the tcdC gene. The mortality rate in confirmed CDI patients with isolates exhibiting deletion in the tcdC gene (2/6, 33.3%), those with isolates harbouring binary toxin genes (2/7, 28.6%), and those with isolates containing mutations in gyrA (2/7, 28.6%) and gyrB (1/2, 50%) was higher than the overall mortality rate (10/50, 20%) in patients with confirmed CDI.

Citing Articles

Risk Factors for Infection in Inpatients: A Four-Year (2017-2020) Retrospective Study.

Hsia C, Su H, Chien Y Antibiotics (Basel). 2025; 14(2).

PMID: 40001377 PMC: 11851458. DOI: 10.3390/antibiotics14020133.

Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.

Trifan A, Stanciu C, Girleanu I, Stoica O, Singeap A, Maxim R World J Gastroenterol. 2017; 23(35):6500-6515.

PMID: 29085200 PMC: 5643276. DOI: 10.3748/wjg.v23.i35.6500.

A population-based longitudinal study of Clostridium difficile infection-related hospitalization in mid-age and older Australians.

Chen Y, Glass K, Liu B, Riley T, Korda R, Kirk M Epidemiol Infect. 2016; 145(3):575-582.

PMID: 27780483 PMC: 9507632. DOI: 10.1017/S0950268816002260.

Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease.

Samonis G, Vardakas K, Tansarli G, Dimopoulou D, Papadimitriou G, Kofteridis D Epidemiol Infect. 2015; 144(1):161-70.

PMID: 25989816 PMC: 9507283. DOI: 10.1017/S0950268815000837.

References

Matamouros S, England P, Dupuy B . Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol. 2007; 64(5):1274-88. DOI: 10.1111/j.1365-2958.2007.05739.x. View

Lee N, Huang Y, Hsueh P, Ko W . Clostridium difficile bacteremia, Taiwan. Emerg Infect Dis. 2010; 16(8):1204-10. PMC: 3298294. DOI: 10.3201/eid1608.100064. View

Pasanen T, Kotila S, Horsma J, Virolainen A, Jalava J, Ibrahem S . Comparison of repetitive extragenic palindromic sequence-based PCR with PCR ribotyping and pulsed-field gel electrophoresis in studying the clonality of Clostridium difficile. Clin Microbiol Infect. 2010; 17(2):166-75. DOI: 10.1111/j.1469-0691.2010.03221.x. View

Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S . A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23):2442-9. DOI: 10.1056/NEJMoa051639. View

Dial S, Delaney J, Barkun A, Suissa S . Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2006; 294(23):2989-95. DOI: 10.1001/jama.294.23.2989. View

Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J . Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005; 366(9491):1079-84. DOI: 10.1016/S0140-6736(05)67420-X. View

Pepin J, Alary M, Valiquette L, Raiche E, Ruel J, Fulop K . Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40(11):1591-7. DOI: 10.1086/430315. View

Persson S, Torpdahl M, Olsen K . New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect. 2008; 14(11):1057-64. DOI: 10.1111/j.1469-0691.2008.02092.x. View

Stubbs S, Brazier J, Oneill G, Duerden B . PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol. 1999; 37(2):461-3. PMC: 84342. DOI: 10.1128/JCM.37.2.461-463.1999. View

10.

Lin Y, Huang Y, Tsai P, Lee T, Lee N, Liao C . Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan. Antimicrob Agents Chemother. 2011; 55(4):1701-5. PMC: 3067156. DOI: 10.1128/AAC.01440-10. View

11.

Howell M, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M . Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010; 170(9):784-90. DOI: 10.1001/archinternmed.2010.89. View

12.

Hundsberger T, Braun V, Weidmann M, Leukel P, Sauerborn M, von Eichel-Streiber C . Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem. 1997; 244(3):735-42. DOI: 10.1111/j.1432-1033.1997.t01-1-00735.x. View

13.

McFarland L, Surawicz C, Stamm W . Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990; 162(3):678-84. DOI: 10.1093/infdis/162.3.678. View

14.

Chung C, Wu C, Lee H, Yan J, Chang C, Lee N . Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. J Microbiol Immunol Infect. 2010; 43(2):119-25. DOI: 10.1016/S1684-1182(10)60019-9. View

15.

Cunningham R, Dale B, Undy B, Gaunt N . Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003; 54(3):243-5. DOI: 10.1016/s0195-6701(03)00088-4. View

16.

Goorhuis A, Bakker D, Corver J, Debast S, Harmanus C, Notermans D . Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis. 2008; 47(9):1162-70. DOI: 10.1086/592257. View

17.

Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit J . gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002; 46(11):3418-21. PMC: 128732. DOI: 10.1128/AAC.46.11.3418-3421.2002. View

18.

Leonard J, Marshall J, Moayyedi P . Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007; 102(9):2047-56. DOI: 10.1111/j.1572-0241.2007.01275.x. View

19.

McFarland L, Mulligan M, Kwok R, Stamm W . Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989; 320(4):204-10. DOI: 10.1056/NEJM198901263200402. View

20.

McCarthy D . Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010; 26(6):624-31. DOI: 10.1097/MOG.0b013e32833ea9d9. View